{"Pemoline":{"Synonym":["Pheniminooxazolidinone","Phenoxazole","Phenylisohydantoin","Phenylpseudohydantoin","Azoksodon","Azoxodon","Azoxodone","Betanamin","Centramin","Constimol","Cylert","Cylert Chewable","Dantromin","Deltamin","Deltamine","Endolin","Fenoxazol","Fio","Hyton","Hyton asa","Juston-Wirkstoff","Kethamed","Myamin","NPL 1","Nitan","Notair","Okodon","PIO","Pemolin","Pemolina","Phenalone","Phenilone","Pioxol","Pomoline","Pondex","Ronyl","Senior","Sigmadyn","Sistra","Sistral","Stimul","Stimulol","Tradon","Tradone","Volital","Volitol"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01230","Curator":"ab","Has role":"Drug","DefiningCitation":"http:\/\/www.drugbank.ca\/drugs\/DB01230","Definition":"In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons. Pharmacology: Pemoline belongs to the group of medicines called central nervous system (CNS) stimulants. It is used to treat attention deficit hyperactivity disorder (ADHD). Pemoline stimulates the brain, probably by affecting neurotransmitters, the chemicals in the brain that nerves use to communicate with each other. Mechanism of action: Not Available Drug type: Illicit. Small Molecule. Withdrawn. Drug category: Central Nervous System Stimulants"}}